AstraZeneca PLC
AZN: XLON (GBR)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| GBX 96,826.00 | Mrzl | Bdyqgksxv |
AstraZeneca Looks Well Positioned for Long-Term Growth Aided by Its Strong Pipeline
/s3.amazonaws.com/arc-authors/morningstar/a90c659a-a3c5-4ebe-9278-1eabaddc376f.jpg)
Business Strategy and Outlook
AstraZeneca has built its leading presence in the pharma and biotech industry on patent-protected drugs and a developing pipeline that add up to a wide moat. The replenishment of new drugs is offsetting the past patent losses on gastrointestinal drug Nexium and cholesterol reducer Crestor, and the company is well positioned for growth.